Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18712974 | 0.79 | ADORA2A (0.32) | GAAADORA2AADORA2BSMN1; SMN2LMNA | |
| SCHEMBL12152092 | 0.79 | ADORA2A (0.32) | ADORA2AADORA2B | |
| SCHEMBL6104900 | 0.77 | ADORA2A (0.31) | GAAADORA2AADORA2BSMN1; SMN2LMNA | |
| SCHEMBL20349532 | 0.77 | ADORA2A (0.31) | GAAADORA2AADORA2BSMN1; SMN2LMNA | |
| SCHEMBL23403654 | 0.77 | ALOX15 (0.36) | GAAADORA2AADORA2BSMN1; SMN2LMNA | |
| SCHEMBL23399085 | 0.77 | GAA (0.39) | GAAADORA2AADORA2BALOX15 | |
| SCHEMBL8649530 | 0.75 | ALDH1A1 (0.54) | GAAADORA2AADORA2BALDH1A1SMN1; SMN2 | |
| SCHEMBL18704882 | 0.74 | — | — | |
| SCHEMBL13233140 | 0.73 | GAA (0.59) | GAASMN1; SMN2LMNAHTT | |
| SCHEMBL19504917 | 0.71 | ADORA2A (0.38) | GAAADORA2AADORA2BALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170096425-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096425-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | GAA 2839/4885ADORA2A 2629/4885ADORA2B 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.